1. India Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Concord Biotech Limited

Concord Biotech Limited

CONCORDBIO.BO
Concord Biotech LimitedIN flagBombay Stock Exchange
1,284.00
INR
+3.95
- -
133.79BMarket Cap

Total Valuation

Concord Biotech Limited carries a market capitalization of 133.79B, placing it among publicly traded companies globally. Its enterprise value stands at 101.97B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap133.79B
Enterprise Value101.97B

Share Statistics

Concord Biotech Limited currently has 104.62M shares outstanding.

Shares Outstanding104.62M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

Concord Biotech Limited trades at a trailing price-to-earnings ratio of 40.99. The price-to-sales ratio is 10.08, and the price-to-book ratio stands at 1,016.86.

PE Ratio40.99
PS Ratio10.08
PB Ratio1,016.86
P/TBV Ratio5.28
P/FCF RatioN/A
P/OCF RatioN/A

Enterprise Valuation

On an enterprise value basis, Concord Biotech Limited trades at an EV/EBITDA multiple of 34.81 and an EV/FCF ratio of 47,873.00. The EV/Sales ratio of 9.67 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 34.81 provides insight into valuation relative to core operating earnings.

EV / Sales9.67
EV / EBITDA34.81
EV / EBIT34.81
EV / FCF47,873.00

Financial Position

Concord Biotech Limited maintains a current ratio of 7.39, meaning it holds 7.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.11, indicating conservative leverage, while an interest coverage ratio of 1,034.40 demonstrates limited ability to service its debt obligations.

Current Ratio7.39
Quick Ratio2.61
Debt / Equity0.11
Debt / EBITDA0.01
Interest Coverage1,034.40

Financial Efficiency

Concord Biotech Limited posts a return on equity of 30.32 and a return on invested capital of 11.48.

Return on Equity (ROE)30.32
Return on Assets (ROA)12.16
Return on Invested Capital (ROIC)11.48
Return on Capital Employed (ROCE)30.32
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover0.87

Taxes

Over the trailing twelve months, Concord Biotech Limited has paid 854.18M in income taxes, reflecting an effective tax rate of 24.78.

Income Tax854.18M
Effective Tax Rate24.78

Stock Price Statistics

Concord Biotech Limited's stock has declined approximately -27.12206% over the past 52 weeks. The 50-day moving average sits at 1,206.63, while the 200-day moving average is 1,287.43.

Beta (5Y)N/A
52-Week Price Change-27.12206%
50-Day Moving Average1,206.63
200-Day Moving Average1,287.43
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Concord Biotech Limited generated 10.55B in revenue and converted that into 2.60B in net income, yielding earnings per share of 24.76. EBITDA reached 2.93B, while operating income came in at 2.93B.

Revenue10.55B
Gross Profit8.09B
Operating Income2.93B
Pretax Income3.45B
Net Income2.60B
EBITDA2.93B
EBIT2.93B
Earnings Per Share (EPS)24.76

Balance Sheet

Concord Biotech Limited holds 4.41B in cash and equivalents against 23.16M in total debt, resulting in a net debt position of -121.86M. Total book value stands at 104.62M, with working capital of 10.81B providing operational flexibility.

Cash & Cash Equivalents4.41B
Total Debt23.16M
Net Debt-121.86M
Equity (Book Value)104.62M
Book Value Per Share1.00
Working Capital10.81B

Margins

Concord Biotech Limited operates with a gross margin of 76.71, reflecting its pricing power and cost economics. The operating margin of 27.77 and net profit margin of 24.60 provide insight into operational efficiency.

Gross Margin76.71
Operating Margin27.77
Pretax Margin32.67
Profit Margin24.60
EBITDA Margin27.77

Scores

Concord Biotech Limited posts an Altman Z-Score of 30.55, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score30.55